Could we begin with a brief overview of Aronex Pharmaceuticals?
Dr. Cox: The company is based in The Woodlands, Texas, which is just north of Houston. We developed a technology that came out of M.D. Anderson Cancer Center, which is a major cancer center based in Houston. We started in 1986 and went public in 1992. The company is not a basic-discovery company its a product-development company. It focuses on taking potential pharmaceutical products through the development process into the commercial arena. The focus of the company is on cancer and infectious diseases. We have four products in development, two of which are in an advanced stage, including one product that is presently under review by the FDA for approval. We are publicly traded on the NASDAQ under the symbol ARNX. TWST: Could you describe the products? Dr. Cox: The product that is currently being reviewed by the FDA is Atragen, a liposomal formulation of all-trans-retinoic acid. It is currently under review for an indication in acute promyelocytic leukemia. Were also pursuing a number
